Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daromun neoadjuvant treatment in stage III melanoma
NCT03567889Phase 3Recruiting
- Sponsor
- Philogen
- Start
- Sep 2018
- Primary completion
- Dec 2027
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 3
01
Overview
A Phase 3 trial of darleukin in melanoma, sponsored by Philogen. Started Sep 2018; status: recruiting.
02
Drugs
darleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03567889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03567889.